A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.

doi:10.1158/1078-0432.CCR-14-1998

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2015

Owonikoko Taofeek K, Ramalingam Suresh S, Miller Daniel L, Force Seth D, Sica Gabriel L, Mendel Jennifer, Chen Zhengjia, Rogatko Andre, Tighiouart Mourad, Harvey R Donald, Kim Sungjin, Saba Nabil F, Pickens Allan, Behera Madhusmita, Fu Robert W, Rossi Michael R, Auffermann William F, Torres William E, Bechara Rabih, Deng Xingming, Sun Shi-Yong, Fu Haian, Gal Anthony A, Khuri Fadlo R

Abstract excerpt

PURPOSE: The altered PI3K/mTOR pathway is implicated in lung cancer, but mTOR inhibitors have failed to demonstrate efficacy in advanced lung cancer. We studied the pharmacodynamic effects of everolimus in resectable non-small cell lung cancer (NSCLC) to inform further development of these agents in lung cancer. EXPERIMENTAL DESIGN: We enrolled 33 patients and obtained baseline tumor biopsy and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Carcinoma, Non-Small-Cell Lung

Share to Everolimus

Share to Fluorodeoxyglucose F18

Share to Neoplasm Staging

Share to Positron-Emission Tomography

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 25673697
DOI: 10.1158/1078-0432.CCR-14-1998
PMCID: PMC4401630

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.PMID 25673697Read ↗

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.Semantic proximity Read ↗

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read ↗

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.Semantic proximity Read ↗

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancerSemantic proximity Read ↗

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.Semantic proximity Read ↗

Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.Semantic proximity Read ↗

Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.Semantic proximity Read ↗

A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.Semantic proximity Read ↗

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivoSemantic proximity Read ↗

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.Semantic proximity Read ↗

Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.